Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.

about

Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.

P2860

Q52571238-2AC9D497-EB20-4528-8112-355F465767FE

P2860

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.

Item

http://www.wikidata.org/entity/Q40754987

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prognostic Significance of Ear ...... -Institutional Study in Japan.

@en

type

Item

label

Prognostic Significance of Ear ...... -Institutional Study in Japan.

@en

prefLabel

Prognostic Significance of Ear ...... -Institutional Study in Japan.

@en

P1476

Prognostic Significance of Ear ...... -Institutional Study in Japan.

@en

P2093

Hideaki Miyake

http://www.w3.org/2001/XMLSchema#string

Ken-Ichi Harada

http://www.w3.org/2001/XMLSchema#string

Masato Fujisawa

http://www.w3.org/2001/XMLSchema#string

Seiichiro Ozono

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.

P2888

s40291-016-0206-3

P304

385-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40291-016-0206-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27178184

http://www.w3.org/2001/XMLSchema#string

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.

about

P2860

P2860

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698